Takeda files for azilsartan fixed-dose combo in US
This article was originally published in Scrip
Executive Summary
Takeda has submitted a US NDA for a fixed-dose combination of azilsartan medoxomil and chlorthalidone. The product is the first to combine an angiotensin II antagonist with chlorthalidone, a long-acting thiazide-like diuretic first introduced in the 1960s and available generically.